Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification
- PMID: 23326163
- PMCID: PMC3542754
- DOI: 10.3748/wjg.v19.i1.57
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification
Abstract
Aim: To compare noninvasive methods presently used for steatosis detection and quantification in nonalcoholic fatty liver disease (NAFLD).
Methods: Cross-sectional study of subjects from the general population, a subgroup from the First Israeli National Health Survey, without excessive alcohol consumption or viral hepatitis. All subjects underwent anthropometric measurements and fasting blood tests. Evaluation of liver fat was performed using four noninvasive methods: the SteatoTest; the fatty liver index (FLI); regular abdominal ultrasound (AUS); and the hepatorenal ultrasound index (HRI). Two of the noninvasive methods have been validated vs liver biopsy and were considered as the reference methods: the HRI, the ratio between the median brightness level of the liver and right kidney cortex; and the SteatoTest, a biochemical surrogate marker of liver steatosis. The FLI is calculated by an algorithm based on triglycerides, body mass index, γ-glutamyl-transpeptidase and waist circumference, that has been validated only vs AUS. FLI < 30 rules out and FLI ≥ 60 rules in fatty liver.
Results: Three hundred and thirty-eight volunteers met the inclusion and exclusion criteria and had valid tests. The prevalence rate of NAFLD was 31.1% according to AUS. The FLI was very strongly correlated with SteatoTest (r = 0.91, P < 0.001) and to a lesser but significant degree with HRI (r = 0.55, P < 0.001). HRI and SteatoTest were significantly correlated (r = 0.52, P < 0.001). The κ between diagnosis of fatty liver by SteatoTest (≥ S2) and by FLI (≥ 60) was 0.74, which represented good agreement. The sensitivity of FLI vs SteatoTest was 85.5%, specificity 92.6%, positive predictive value (PPV) 74.7%, and negative predictive value (NPV) 96.1%. Most subjects (84.2%) with FLI < 60 had S0 and none had S3-S4. The κ between diagnosis of fatty liver by HRI (≥ 1.5) and by FLI (≥ 60) was 0.43, which represented only moderate agreement. The sensitivity of FLI vs HRI was 56.3%, specificity 86.5%, PPV 57.0%, and NPV 86.1%. The diagnostic accuracy of FLI for steatosis > 5%, as predicted by SteatoTest, yielded an area under the receiver operating characteristic curve (AUROC) of 0.97 (95% CI: 0.95-0.98). The diagnostic accuracy of FLI for steatosis > 5%, as predicted by HRI, yielded an AUROC of 0.82 (95% CI: 0.77-0.87). The κ between diagnosis of fatty liver by AUS and by FLI (≥ 60) was 0.48 for the entire sample. However, after exclusion of all subjects with an intermediate FLI score of 30-60, the κ between diagnosis of fatty liver by AUS and by FLI either ≥ 60 or < 30 was 0.65, representing good agreement. Excluding all the subjects with an intermediate FLI score, the sensitivity of FLI was 80.3% and the specificity 87.3%. Only 8.5% of those with FLI < 30 had fatty liver on AUS, but 27.8% of those with FLI ≥ 60 had normal liver on AUS.
Conclusion: FLI has striking agreement with SteatoTest and moderate agreements with AUS or HRI. However, if intermediate values are excluded FLI has high diagnostic value vs AUS.
Keywords: Agreement; Fatty liver index; Hepatorenal ultrasound index; Screening; Sensitivity; Specificity; SteatoTest; Steatosis.
Figures




Similar articles
-
External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study.Clin Gastroenterol Hepatol. 2013 Sep;11(9):1201-4. doi: 10.1016/j.cgh.2012.12.031. Epub 2013 Jan 22. Clin Gastroenterol Hepatol. 2013. PMID: 23353640
-
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.Liver Int. 2012 Jul;32(6):911-8. doi: 10.1111/j.1478-3231.2012.02820.x. Liver Int. 2012. PMID: 22672642
-
Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.World J Gastroenterol. 2016 Mar 14;22(10):3023-30. doi: 10.3748/wjg.v22.i10.3023. World J Gastroenterol. 2016. PMID: 26973398 Free PMC article.
-
Revisiting the Hepatorenal Index in the Quantification of Hepatic Steatosis: How it is done and the utility.Ultrasound Q. 2024 Jun 18;40(3):e00681. doi: 10.1097/RUQ.0000000000000681. eCollection 2024 Sep 1. Ultrasound Q. 2024. PMID: 38889400 Review.
-
Fatty liver index (FLI): more than a marker of hepatic steatosis.J Physiol Biochem. 2024 Feb;80(1):11-26. doi: 10.1007/s13105-023-00991-z. Epub 2023 Oct 25. J Physiol Biochem. 2024. PMID: 37875710 Review.
Cited by
-
High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study.Nutr Metab Cardiovasc Dis. 2019 Feb;29(2):191-200. doi: 10.1016/j.numecd.2018.10.008. Epub 2018 Oct 31. Nutr Metab Cardiovasc Dis. 2019. PMID: 30573307 Free PMC article.
-
Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean national health and nutrition examination survey (KNHANES).Inflammopharmacology. 2021 Aug;29(4):1111-1118. doi: 10.1007/s10787-021-00842-7. Epub 2021 Jul 16. Inflammopharmacology. 2021. PMID: 34269951
-
A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study.PLoS One. 2015 Nov 30;10(11):e0143560. doi: 10.1371/journal.pone.0143560. eCollection 2015. PLoS One. 2015. PMID: 26618774 Free PMC article.
-
Associations between steatotic liver disease subtypes and incident atrial fibrillation in young adults: a nationwide cohort study.Cardiovasc Diabetol. 2025 Aug 25;24(1):348. doi: 10.1186/s12933-025-02905-3. Cardiovasc Diabetol. 2025. PMID: 40855552 Free PMC article.
-
Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease.Sci Rep. 2022 Jun 23;12(1):10681. doi: 10.1038/s41598-022-14856-w. Sci Rep. 2022. PMID: 35739172 Free PMC article.
References
-
- Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis. 2010;28:162–168. - PubMed
-
- Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208–1216. - PMC - PubMed
-
- Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–117. - PubMed
-
- Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol. 2004;3:63–65. - PubMed
-
- Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int. 2006;26:856–863. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous